Publications en collaboration avec des chercheurs de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (240)

2024

  1. Animal models of disease: Achievements and challenges

    Methods in Cell Biology

  2. Calbindin and Girk2/Aldh1a1 define resilient vs vulnerable dopaminergic neurons in a primate Parkinson’s disease model

    npj Parkinson's Disease, Vol. 10, Núm. 1

  3. Characterization of brain transduction capability of a BBB-penetrant AAV vector in mice, rats and macaques reveals differences in expression profiles

    Gene Therapy, Vol. 31, Núm. 9-10, pp. 455-466

  4. Development and characterization of a non-human primate model of disseminated synucleinopathy

    Frontiers in Neuroanatomy, Vol. 18

  5. Development of an in vitro platform for the analysis of contractile and calcium dynamics in single human myotubes

    Lab on a Chip, Vol. 24, Núm. 20, pp. 4741-4754

  6. Levodopa-Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5-Year Follow-Up Study

    Movement Disorders Clinical Practice, Vol. 11, Núm. 7, pp. 830-849

  7. Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus

    Movement Disorders, Vol. 39, Núm. 2, pp. 235-248

  8. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  9. Preface

    Methods in Cell Biology

  10. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

  11. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

  12. The causal role of the subthalamic nucleus in the inhibitory network

    Annals of the New York Academy of Sciences, Vol. 1538, Núm. 1, pp. 117-128

  13. The cellular prion protein does not affect tau seeding and spreading of sarkosyl-insoluble fractions from Alzheimer’s disease

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 110

  2. A second update on mapping the human genetic architecture of COVID-19

    Nature

  3. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

    Brain, Behavior, and Immunity, Vol. 108, pp. 255-268

  4. Boolean analysis shows a high proportion of dopamine D2 receptors interacting with adenosine A2A receptors in striatal medium spiny neurons of mouse and non-human primate models of Parkinson's disease

    Neurobiology of Disease, Vol. 188

  5. Engineering U1-Based Tetracycline-Inducible Riboswitches to Control Gene Expression in Mammals

    ACS Nano, Vol. 17, Núm. 23, pp. 23331-23346

  6. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  7. Interactions between functional networks in Parkinson's disease mild cognitive impairment

    Scientific Reports, Vol. 13, Núm. 1